Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?
- PMID: 20516442
- DOI: 10.1200/JCO.2010.29.7077
Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?
Comment on
-
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.J Clin Oncol. 2010 Jul 1;28(19):3107-14. doi: 10.1200/JCO.2009.25.4037. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516432 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
